IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Public ClinicalTrials.gov record NCT01732796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of the study is to confirm efficacy of treatment for 16 and 24 weeks in chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
Study identification
- NCT ID
- NCT01732796
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Interventions
- Ribavirin (RBV) Drug
- BI 201335 (Faldaprevir) Drug
- BI 207127 Drug
- Faldaprevir (BI 201335) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2012 (Type not available)
- Primary completion
- Jan 2015 (Actual)
- Completion
- Jan 2015 (Actual)
- Last update posted
- Apr 18, 2016
2012 – 2015
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1241.20.00026 Boehringer Ingelheim Investigational Site | Dothan | Alabama | — | — |
| 1241.20.00033 Boehringer Ingelheim Investigational Site | Chula Vista | California | — | — |
| 1241.20.00006 Boehringer Ingelheim Investigational Site | La Mesa | California | — | — |
| 1241.20.00003 Boehringer Ingelheim Investigational Site | Oceanside | California | — | — |
| 1241.20.00008 Boehringer Ingelheim Investigational Site | Poway | California | — | — |
| 1241.20.00015 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1241.20.00014 Boehringer Ingelheim Investigational Site | Ft. Pierce | Florida | — | — |
| 1241.20.00004 Boehringer Ingelheim Investigational Site | Maitland | Florida | — | — |
| 1241.20.00010 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1241.20.00001 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1241.20.00018 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1241.20.00002 Boehringer Ingelheim Investigational Site | Chevy Chase | Maryland | — | — |
| 1241.20.00032 Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| 1241.20.00009 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 1241.20.00016 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1241.20.00031 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1241.20.00019 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1241.20.00024 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 1241.20.00013 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1241.20.00005 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1241.20.00017 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1241.20.00012 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1241.20.00022 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1241.20.00020 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01732796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 18, 2016 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01732796 live on ClinicalTrials.gov.